2007: RA New and Established Therapies: Efficacy and Safety I
Search or Browse by Day

RA New and Established Therapies: Efficacy and Safety I

256
Initial versus Delayed Treatment with Infliximab plus Methotrexate in Patients with Recent Onset Rheumatoid Arthritis: Results from the BeSt Study
257
Extended Follow-up of the Long-term Safety of Rituximab in Rheumatoid Arthritis
258
Evaluation of the Clinical Relevance of Different Reporting Techniques Used to Assess Disease Activity in RA Clinical Trials from the Patient’s Perspective: New Insights from the Abatacept database
259
Relationship Between Serum Concentrations of the Interleukin-6 Receptor Inhibitor Tocilizumab and C-Reactive Protein Reduction in RA Patients: 6 Months’ Data from a Phase 3 Study
260
Why do Women with Early RA Respond Less Well to MTX then Men? Gender as a Determinant of Clinical Response in the Initial Open-label Phase of the Swefot Clinical Trial
261
Immunoglobulin Levels and Infection Rates in Patients with Rheumatoid Arthritis (RA) Treated With Repeated Courses of Rituximab
262
Safety of TNF Inhibitors and Non-Biologic DMARDs in Rheumatoid Arthritis Patients Previously Treated with Rituximab
264
Reduction of Oxidized LDL Levels and Raised Atheroprotective Natural Antibodies Against Phosphorylcholine Induced by Gluten-Free Vegan Diet in Patients with Rheumatoid Arthritis are Partly Dependant on Decreased Disease Activity
265
Efficacy of Etanercept in Early Versus Long-Term Rheumatoid Arthritis: Posthoc Analysis of 3-year TEMPO Data
266
Repeated Treatment Courses of Rituximab Produce Sustained Efficacy in Rheumatoid Arthritis Patients with an Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs
267
Consistent Inhibition of Structural Damage Progression by Rituximab in Medically Important Subgroups of Patients with an Inadequate Response to TNF Inhibitors: Week 56 REFLEX Results
268
Anti-tnf Treatment with Adalimumab Reduces Hand Bone Loss in Early Rheumatoid Arthritis (RA): Explorative Analyses from the Premier Study
269
Results from a Randomized, Blinded, Single-dose, Placebo- and Anakinra-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 108 (a Fhuman Monoclonal Antibody to IL-1R type I) in Healthy Volunteers
270
The Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects with Rheumatoid Arthritis on a Background of Methotrexate Therapy
271
Vascular Endothelial Dysfunction in Patients with Rheumatoid Arthritis can be Reversed by Adalimumab Treatment
272
Improved Clinical and Simplified Disease Activity Index (CDAI, SDAI) Scores with Rituximab in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors
273
Good Quality of Life as Assessed by SF-36 in Patients with Early Rheumatoid Arthritis Treated with a Combination of Three DMARDs and Prednisolone with or without Infliximab
274
Characterization of Golimumab (CNTO 148), a Novel Monoclonal Antibody Specific for Human TNFα
275
Monitoring the Effects of Leflunomide by Dynamic Magnetic Resonance Imaging in Patients with Active Rheumatoid Arthritis: Correlation with Changes in Biochemical Markers
276
Chronic Dosing with Diclofenac versus Etoricoxib or Celecoxib: Differences in Pharmacodynamic Profiles of COX-1 and COX-2 Inhibition
277
Certolizumab Pegol 400 mg Every 4 Weeks as Monotherapy Rapidly Reduces Disease Activity in Active Rheumatoid Arthritis
278
The Effect of Adalimumab on Clinical and MRI Outcome Measures in Psoriatic Arthritis
279
Anti TNF-α Agents in Adult Onset Still Disease. A 4 Year Follow-up Study
280
Contemporary Use of Abatacept in Rheumatoid Arthritis
281
Are COX-2’s Safe to Use in Patients on Warfarin?
282
TNF Inhibitors (TNF-I) and Risk of Malignancy in 8,072 RA Patients Followed Over 15,495 Patient Years
283
Definitive Results of the National French Prospective RATIO 3-Year Observatory on Lymphomas in Patients Treated with TNF Blockers : No Increase of Non Hodgkin’s Lymphomas but Slight Increase of EBV-Positive Hodgkin’s and Hodgkin Like’s L
284
Influence of Infliximab on the Myocardial Function of Patients with Rheumatic Diseases-12 Month Follow-Up
285
Tuberculosis in Japanese Patients with Rheumatoid Arthritis Treated with Infliximab: Findings from the Post Marketing Surveillance Trial
286
Increasing Cholesterol after Start of Adalimumab Treatment in Patients with Rheumatoid Arthritis, but no Negative Effect on the ApoB/apoA1 Lipoprotein Ratio
287
TNF-α Antagonists and Risk of Severe Infections in Patients with Secondary Amyloidosis Complicating Inflammatory Artropathies
288
Infusion-Associated Events in Patients with Rheumatoid Arthritis Receiving Rituximab: Preliminary Results from SUNRISE
289
Daily and Cumulative Threshold Glucocorticoid Dose Associated with Cardiovascular and All-Cause Mortality in Rheumatoid Arthritis
290
Sequencing of DMARD Therapy in a Cohort of Newly Diagnosed Rheumatoid Arthritis (RA) Patients in the US: An Analysis of 16,752 RA Patients, 1998 - 2006
291
The Effectiveness and Cost-Effectiveness of Anti-TNF Therapy in the Community
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>